Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Jose F. Falantes"'
Autor:
Jose F, Falantes, Francisco J, Márquez-Malaver, Estrella, Carrillo, Marta García, Culebras, Rosario, Morales, Concepción, Prats, Maria T, Vargas, Teresa, Caballero, Eduardo, Rodríguez-Arbolí, Ildefonso, Espigado, Jose Antonio, Pérez-Simón
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e1059-e1066
[Introduction] Prognosis of patients with myelodysplastic syndrome (MDS), particularly the group with lower-risk disease (LR-MDS) is very heterogeneous. Several studies have described the prognostic value of recurrent somatic mutations in MDS includi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30f61141dd9143ca59e143b4f79ad090
https://doi.org/10.1016/j.clml.2022.08.012
https://doi.org/10.1016/j.clml.2022.08.012
Autor:
Jose F. Falantes, Francisco J. Márquez-Malaver, Estrella Carrillo-Cruz, Rosario M Morales-Camacho, Concepción Prats-Martín, Teresa Caballero, Eduardo Rodriguez Arbolí, Ildefonso Espigado, Jose A. Perez-Simon
Publikováno v:
Blood. 140:6920-6922
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14562f1091b3cd15188f06922e82a1f3
https://doi.org/10.1182/blood-2022-169372
https://doi.org/10.1182/blood-2022-169372
Autor:
Rosario M. Morales Camacho, Javier Sanchez, Irene Marcos Luque, Ricardo Bernal, Jose F Falantes, Jose A Pérez-Simón
Publikováno v:
Case Reports in Genetics, Vol 2014 (2014)
Refractory anaemia with ring sideroblasts and marked thrombocytosis (RARS-T) is a provisional entity in the World Health Organization (WHO) classification. It displays features characteristic of both myelodysplastic syndrome and myeloproliferative ne
Externí odkaz:
https://doaj.org/article/ef367eeb794440209ce5ba07f03e7417
Autor:
Paresh Vyas, Dietger Niederwieser, Rena Buckstein, David Valcárcel, Valentina Giai, Gianluigi Reda, C.L. Beach, Guillermo Garcia-Manero, Ignazia La Torre, Jake Shortt, Valeria Santini, Barry S. Skikne, Moshe Mittelman, Lewis R. Silverman, Uwe Platzbecker, Jianhua Zhong, Anna Jonasova, Aristoteles Giagounidis, Luana Fianchi, Maria Diez Campelo, Pierre Fenaux, Stephen Larsen, Esther Oliva, Eric Laille, Antonio Almeida, Francesco Buccisano, Jose F Falantes, Daniel Menezes
PURPOSE Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Sc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4292672c790570d7eb0a77b548d74e12
http://hdl.handle.net/2108/283551
http://hdl.handle.net/2108/283551
Autor:
Amy E. DeZern, Michael R. Savona, Rami S. Komrokji, Dominiek Mazure, Uwe Platzbecker, Osman Ilhan, Diana Ronai Dunshee, María Díez-Campelo, Ulrich Germing, Lionel Ades, Paresh Vyas, David T. Bowen, Thomas Cluzeau, Edo Vellenga, Peter L. Greenberg, Jennie Zhang, Ghulam J. Mufti, Rena Buckstein, Joseph G. Jurcic, Amit Verma, Mario Cazzola, Jose F Falantes, Carlo Finelli, Mikkael A. Sekeres, Peter G. Linde, Aziz Benzohra, Amer M. Zeidan, Katharina Goetze, Eva Hellström-Lindberg, Pierre Fenaux, Valeria Santini, Bruno Quesnel, Dominik Selleslag, Alan F. List, Maria-Teresa Voso, Guillermo Garcia-Manero, Abderrahmane Laadem, Anita Rampersad, Beatriz Arrizabalaga, Valentina Giai, Matthew L. Sherman, Flavia Salvi, Odile Beyne-Rauzy
Publikováno v:
New England Journal of Medicine, 382(2), 140-151. MASSACHUSETTS MEDICAL SOC
Background: Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds tra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::580e03b5b5c3216eaafec49607c7466d
https://ora.ox.ac.uk/objects/uuid:57417502-f731-49ea-8a6d-264ac5c4e064
https://ora.ox.ac.uk/objects/uuid:57417502-f731-49ea-8a6d-264ac5c4e064
Autor:
Regina Brown, Heather A. Leitch, David Valcárcel, Blanca Xicoy, Daniel Morillo, Laurie Lenox, David Lavie, Ana Alfonso, Manish R. Patel, Josh Lauring, Pankaj Mistry, Uwe Platzbecker, Jaydeep Mehta, Friederike Pastore, Jörg Chromik, Irit Avivi, Tamanna Haque, Andrew M. Brunner, Meir Preis, Anna Kalota, Félix López Cadenas, Jose F Falantes, Ulrich Germing
Publikováno v:
Blood. 138:2606-2606
Background Myelodysplastic syndromes (MDS) are characterized by frequent mutations in RNA splicing factor genes. Protein arginine methyltransferase 5 (PRMT5) regulates the activity of the splicing machinery through methylation of key spliceosome prot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ef2caebbdf579e6646b55ba8c7bcb1b
https://doi.org/10.1182/blood-2021-146987
https://doi.org/10.1182/blood-2021-146987
Autor:
Susana Vives, Lourdes Escoda, Josep-Maria Ribera, Antonia Sampol, Ferran Vall-Llovera, Montserrat Hoyos, David Valcárcel, Jose F Falantes, M. Luz Amigo, J. Pio Torres, Marisa Calabuig, Olga Salamero, Antonio Garcia-Guiñon, Joan Bargay, Maria Paz Queipo De Llano, Merchan Brayan, Jordi Esteve, David Gallardo, Salut Brunet, Xavier Ortín, Anna Sureda Balari, Montserrat Arnan, Jorge Sierra, Ana Garrido, Marina Díaz-Beyá, Mar Tormo, José M. Moraleda
Publikováno v:
Blood. 136:13-14
BACKGROUND: The progress in the understanding of pathophysiology of AML has allowed the identification of genetic and immune abnormalities with prognostic impact on outcome and suitable as therapeutic targets. The genetic abnormalities are essential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85171763ac4d2513a092912fc94fcb47
https://doi.org/10.1182/blood-2020-140680
https://doi.org/10.1182/blood-2020-140680
Autor:
Francisco J. Márquez-Malaver, José A. Pérez-Simón, Cristina Calderón-Cabrera, Teresa Knight, Jose F Falantes, Isabel Montero, José González, Ildefonso Espigado, Maria Luz Martino
Publikováno v:
Leukemia & Lymphoma. 58:1893-1902
Chronic medical diseases, evaluated by several comorbidities indexes have been reported to influence on overall survival in patients with myelodysplastic syndrome (MDS). However, these studies included patients with lower and higher-risk disease by I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d58cbf6cff7e71410748859d64382fc
https://doi.org/10.1080/10428194.2016.1267350
https://doi.org/10.1080/10428194.2016.1267350
Autor:
Jose F Falantes, Felipe Prosper, Jose Luis Lopez Lorenzo, Inmaculada Rapado, Pilar Herrera, Olga Salamero, Bruno Paiva, Joaquin Martinez Lopez, Juan Miguel Bergua Burgues, Fernando Ramos, Eva Barragán, María-Belén Vidriales, Laura Rufian, Cristina Gil, Maria Jose Sayas, Jesús Lorenzo Algarra, Josefina Serrano, Pilar Rodríguez Martínez, Jorge Labrador, Mar Tormo, Alexandra Juarez, David Martínez-Cuadrón, Susana Vives, Rosa Ayala, Esperanza Lavilla, Miguel A. Sanz, Esther Onecha, Pau Montesinos Fernandez
Publikováno v:
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
BACKGROUND: Older patients with acute myeloid leukaemia (AML) who are unsuitable for standard induction therapy have limited treatment options. While DNMT3A, TET2, IDH1/2 and TP53 mutations have been previously associated to better response to hypome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45e0d58b70a93339213272e741f9fd99
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4345
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4345
Autor:
Jun Ho Jang, Antonio Almeida, Gail J. Roboz, Dominik Selleslag, Paula Marlton, Maria Teresa Voso, Hagop M. Kantarjian, Jose F Falantes, Pau Montesinos, Sanjay R. Mohan, Guillermo Garcia-Manero, Barry S. Skikne, Farhad Ravandi, Kimmo Porkka, Andrew H. Wei, Hamid Sayar
Publikováno v:
Future Oncology
FUTURE ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
FUTURE ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Older patients with acute myeloid leukemia (AML) have worse rates of complete remission and shorter overall survival than younger patients. The epigenetic modifier CC-486 is an oral formulation of azacitidine with promising clinical activity in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56299bcf578b99748d10b6fa003cbee4
https://doi.org/10.2217/fon.15.326
https://doi.org/10.2217/fon.15.326